Complex haplotypic effects of the ABCB1 gene on epilepsy treatment response

Pharmacogenomics

Volumn 6, Issue 4, 2005, Pages 411-417

  Hung, Chin Chuan ^a   Tai, John Jen ^a   Lin, Chun Jung ^a   Lee, Ming Jen ^a   Liou, Horng Huei ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Epilepsy; Haplotype; Linkage disequilibrium; MDR1; Multi drug resistance

Indexed keywords

ABC TRANSPORTER; ANTICONVULSIVE AGENT; MULTIDRUG RESISTANCE PROTEIN 1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG RESPONSE; EPILEPSY; EXON; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC POLYMORPHISM; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ADULT; ALLELES; ANTICONVULSANTS; DRUG RESISTANCE; EPILEPSY; EXONS; FEMALE; GENOTYPE; HAPLOTYPES; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; TAIWAN;

EID: 21444449353     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/14622416.6.4.411     Document Type: Article

References (30)

1. MacDonald BK, Johnson AL, Goodridge DM, Cockerell OC, Sander JW, Shorvon SD: Factors predicting prognosis of epilepsy after presentation with seizures. Ann. Neurol. 48, 833-841 (2000).
2. Loscher W, Potschka H: Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J. Pharmacol. Exp. Ther. 301, 7-14 (2002).
3. Fromm MF: P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int. J. Clin. Pharmacol. Ther. 38, 69-74 (2000).
4. Zhang Y, Benet LZ: The gut as a barrier to drug absorption. Combined role of cytochrome P4503A and P-glycoprotein. Clin. Pharmacokinet. 40, 159-168 (2001).
5. Schinkel A: The physiological function of drug-transporting P-glycoproteins. Semin. Cancer. Biol. 8, 161-170 (1997).
6. Tishler DM, Weinberg KI, Hinton DR, Barbaro N, Annett GM, and Raffel C: MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 36, 1-6 (1995).
7. Dombrowski SM, Desai SY, Marroni M et al.: Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia 42, 1501-1506 (2001).
8. Sakaeda T, Nakamura T, Okumura K: Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics 4, 397-410 (2003).
9. Hoffmeyer S, Burk O, von Richter O et al.: Functional polymorphism of the human mutidrug-resistance gene: multiple sequence variations and correlation ofone allele with P-glycoprotien expression and activity in vivo. Proc. Natl. Acad. Sci. USA 97, 3473-3478 (2000).
10. Siddiqui A, Kerb R, Weale ME et al.: Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N. Engl. J. Med. 348, 1442-1448 (2003).
11. Zimprich F, Sunder-Plassmann R, Stogmann E et al. Association of an ABCB1 gene haplotype with pharmacoresistance in temporal lobe epilepsy. Neurology 63, 1087-1089 (2004).
12. Nakamura T, Sakaeda T, Horinouchi M et al. Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin. Pharmacol. Ther. 71, 297-303 (2002).
13. Tan N, Heron S, Scheffer I et al. Failure to confirm association of a polymorphism in ABCB1 with multidrug-resistant epilepsy. Neurology 63, 1090-1092 (2004).
14. Commission of Classification and Terminology of the International League Against Epilepsy: Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 30, 389-399 (1989).
15. Siegmund W, Ludwig K, Giessmann T et al.: The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin. Pharmcol. Ther. 72, 572-583 (2002).
16. Clark AG: Inference of haplotypes from PCR-amplified samples of diploid populations. Mol. Bio. Evol. 7, 111-122 (1990).
17. Weir BS: Genetic-data analysis II: methods for discrete population genetic data. Sinauer Associates, Sunderland, Mass, USA (1996).
18. Johne A, Kopke K, Gerloff T et al.: Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin. Pharmacol. Ther. 72, 584-594 (2002).
19. Tang K, Ngoi SM, Gwee PC et al.: Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 12, 437-450 (2002).
20. Kroetz DL, Pauli-Magnus C, Hodges LM et al.: Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 13, 481-494 (2003).
21. Chowbay B, Cumaraswamy S, Cheung YB et al.: Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics 13, 89-95 (2003).
22. Hitzl M, Schaeffeler E, Hocher B et al.: Variable expression of P-glycoprotein in the human placenta and its association with mutations of the multidrug resistance 1 gene (MDR1, ABCB1). Pharmacogenetics 14, 309-318 (2004).
23. Goldstein DB: Islands of linkage disequilibrium. Nature Genet. 29, 109-111 (2001).
24. Kwan P, Brodie MJ: Potential role of drug transporters in the pathogenesis of medically intractable epilepsy. Epilepsia 46, 224-235 (2005).
25. Sisodiya SM, Lin WR, Harding BN et al.: Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain 125, 22-31 (2002).
26. Aronica E, Gorter JA, Ramkema M et al.: Expression and cellular distribution of multidrug resistance-related proteins in the hippocampus of patients with mesial temporal lobe epilepsy. Epilepsia 45, 441-451 (2004).
27. Seegers U, Potschka H and Loscher W: Transient increase of P-glycoprotein expression in endothelium and parenchyma of limbic brain regions in the kainite model of temporal lobe epilepsy. Epilepsy Res. 51, 257-268 (2002).
28. Kim RB, Leake BF, Choo EF et al.: Identification of functionally variant MDR1 alleles among European-Americans and African-Americans. Clin. Pharmacol. Ther. 70, 189-199 (2001).
29. Sai K, Kaniwa N, Itoda M et al.: Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. Pharmacogenetics 13, 741-757 (2003).
30. Goto M, Masuda S, Saito H et al.: C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics 12, 451-457 (2002).